27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Medical device maker Smith & Nephew plc (NYSE: SNN) slips in the premarket after reporting a slump in revenues and profits. Full-year 2020 revenue fell 11.2% Y/Y to $4.6 billion, and operating profit dropped over 60% to $295 million.
- COVID-19 related restrictions swamped other patient care areas, particularly the elective surgeries that require Smith & Nephew’s replacement prosthetic hips and knees.
- For 2020, the trading profit of $683 million almost halved from $1.17 billion recorded for 2019.
- Cash generated from operations reached $972 million in 2020, down from $1,370 million a year ago.
- The company declared a full-year dividend of 37.5 cents per share, unchanged from 2019.
- For 2021, the company expects the COVID-19 impact to continue into the first half of 2021. The timing of recovery remains unclear.
- Smith & Nephew chief executive Roland Diggelmann said: “We start 2021 with three clear priorities: to return to top-line growth and recapture momentum; to drive further operational improvement; to continue to respond effectively to COVID-19.”
- See the Q4 earnings presentation here.
- Price Action: SNN stock dropped 2.93% at $42.68 in the premarket trading on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!